Regeneron Pharmaceuticals, Inc.
REGN
$767.96
$19.252.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.91% | -2.84% | 12.01% | -20.86% | 33.02% |
| Total Depreciation and Amortization | 12.33% | 11.93% | 11.22% | 11.86% | 15.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -462.50% | 46.85% | -108.52% | 351.11% | -155.43% |
| Change in Net Operating Assets | 1,078.09% | 74.91% | -70.58% | -40.72% | 66.77% |
| Cash from Operations | 25.36% | 223.28% | -30.90% | 15.89% | 15.88% |
| Capital Expenditure | 16.74% | -21.33% | -71.25% | 20.60% | -37.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -202.63% | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 40.30% | -123.33% | 156.45% | 197.20% | -23.51% |
| Cash from Investing | 29.86% | -96.34% | 138.38% | 629.61% | -15.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -84.18% | -92.80% | -91.12% | -69.80% | -5.17% |
| Repurchase of Common Stock | 22.02% | -16.53% | -64.68% | -64.15% | -26.54% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -13.23% | -135.98% | -2,412.53% | -154.54% | -55.66% |
| Foreign Exchange rate Adjustments | -150.00% | 233.33% | 220.00% | -450.00% | 500.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 495.10% | -58.07% | 571.88% | -17.38% | -60.29% |